Pacira BioSciences, Inc.
PCRXNASDAQHealthcare● Active
$22.86
+$0.11(+0.48%)
Market Cap$899198100
P/E Ratio—
52W High$27.64
52W Low$18.8
Pacira BioSciences, Inc. (PCRX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · PCRX · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.73B | $0.70B | $0.67B | $0.67B | $0.54B |
| Cost of Revenue | $0.15B | $0.17B | $0.18B | $0.20B | $0.14B |
| Gross Profit | $0.58B | $0.53B | $0.49B | $0.47B | $0.40B |
| Gross Margin %(computed) | 79.39% | 75.69% | 72.64% | 70.11% | 74.10% |
| Operating Expenses | |||||
| R&D Expenses | $0.12B | $0.08B | $0.08B | $0.08B | $0.06B |
| G&A Expenses | $0.14B | $0.12B | $0.12B | $0.11B | $0.09B |
| Total Operating Expenses | $0.54B | $0.60B | $0.40B | $0.41B | $0.31B |
| Operating Income | $0.03B | ($0.07B) | $0.09B | $0.06B | $0.09B |
| Operating Margin %(computed) | 4.58% | -10.47% | 12.99% | 9.00% | 16.61% |
| Interest Income | $0.02B | $0.02B | $0.01B | $0.00B | $0.00B |
| Interest Expense | $0.01B | $0.02B | $0.02B | $0.04B | $0.03B |
| Income Before Tax | $0.02B | ($0.06B) | $0.06B | $0.01B | $0.06B |
| Income Tax Expense | $0.01B | $0.04B | $0.02B | ($0.00B) | $0.01B |
| Net Income | $0.01B | ($0.10B) | $0.04B | $0.02B | $0.04B |
| Net Margin %(computed) | 0.97% | -14.20% | 6.22% | 2.39% | 7.75% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $0.16 | $-2.15 | $0.91 | $0.35 | $0.95 |
| Wtd Avg Shares | 0.04B | 0.05B | 0.05B | 0.05B | 0.04B |
| EBITDA | $0.12B | $0.03B | $0.15B | $0.14B | $0.11B |
| EBITDA Margin %(computed) | 16.86% | 4.15% | 22.90% | 21.05% | 21.04% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Pacira BioSciences, Inc. data
About Pacira BioSciences, Inc. (PCRX) Income Statement
Pacira BioSciences, Inc. (PCRX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, PCRX reported revenue of $0.73B, gross profit of $0.58B (gross margin 79.39%), and net income of $0.01B — a net profit margin of 0.97%.
Frequently asked questions
PCRX · 4 questionsPacira BioSciences, Inc. (PCRX) reported revenue of $0.73B for 2025, up 3.6% year-over-year.
PCRX revenuePCRX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08